Beyond the initial cash injection, the agreement includes the issuance of pre-funded warrants for 1.26 million shares of Evommune stock. Hinova remains positioned for significant long-term upside, with potential milestone-based payments reaching $150 million for development and regulatory benchmarks, plus an additional $920 million tied to further commercial milestones and tiered royalty structures.
In section Market Quotes
Evommune Secures Global Rights to Hinova Glue Degraders in $20M Deal
A $20 million upfront cash payment has secured Evommune exclusive global rights to a suite of glue degraders developed by Hinova Pharmaceuticals. The clinical-stage biotech firm intends to leverage these Vav Guanine Nucleotide Exchange Factor 1 degraders across all human and animal indications, excluding the Chinese market.
To bolster its capital reserves alongside this acquisition, Evommune finalized a private placement of approximately 5 million shares at $6.04 per share. Scheduled to close on November 6, this offering is projected to generate $30 million in gross proceeds to support the company’s expanded pipeline.
Comments (0)
No comments yet. Be the first!